Phosphatidylcholine Metabolic Transformation as a Biomarker
Author Information
Author(s): Aboagye Eric O.
Primary Institution: Comprehensive Cancer Imaging Centre, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London
Hypothesis
Can the phosphatidylcholine transformation and progression signature (PTPS) serve as a pharmacodynamic biomarker for drug effects in cancer treatment?
Conclusion
Normalization of tumor PTPS appears to be a realistic biomarker for non-invasive monitoring of the pharmacological action of Hsp90 inhibitors.
Supporting Evidence
- The study provides proof that Hsp90 inhibitors alter the PTPS of melanoma cells in a predictable manner.
- Imaging and spectroscopic methods that exploit the PTPS may have clinical value as pharmacodynamic biomarkers in melanoma.
- Normalization of PTPS is linked to the pharmacological action of Hsp90 inhibitors.
Takeaway
This study looks at how a specific biomarker can help doctors see if cancer treatments are working without needing to do invasive tests.
Methodology
The study used magnetic resonance spectroscopy (MRS) to assess the metabolic response of melanoma cells to Hsp90 inhibitors.
Limitations
Standard 31P-MRS methods do not sufficiently resolve individual choline metabolite resonances.
Want to read the original?
Access the complete publication on the publisher's website